- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03103724
A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease. (EXCALIBUR)
April 23, 2021 updated by: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Open label, single arm, phase II multicentre study designed to determine the clinical benefit, as measured by 3-months disease control rate (DCR) provided by enzalutamide in metastatic Castration Resistant Prostate Cancer patients with at least one visceral site involvement.
Study Overview
Study Type
Interventional
Enrollment (Actual)
68
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Milan, Italy, 20133
- Elena Verzoni
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Age > 18
- ECOG PS 0-1-2
- Biopsy (primary tumour or metastases) confirming the diagnosis of prostate adenocarcinoma
- Documented measurable metastatic visceral disease (according to RECIST 1.1 criteria) considering metastases in lung or liver or extraregional lymphnodes
- Written informed consent
- Platelets > or = 100 x109/L; haemoglobin > or = 9 g/dl; neutrophils > or 1.5 x 109/L
- Bilirubin < or = 2 mg/dl, AST and ALT < or = 2.5 times the UNL or < or = 5 times UNL for pts with liver metastases; serum albumin > or = the LNL
- Patients of childbearing age should use contraceptive methods
- Life expectancy > 3 months
- Able to swallow the study drug and comply with study requirements;
- Willing and able to give informed consent.
- Ongoing androgen deprivation therapy with a GnRH analogue or orchiectomy (i.e., surgical or medical castration);
- Patients may have received previous therapy including chemotherapy (docetaxel) last cycle must be received 3 weeks before start of experimental treatment. Hormonal treatment containing bicalutamide must be interrupted 2 weeks before start of study therapy
- Previous radiotherapy (prostate and/or bone) is accepted but must be interrupted 3 weeks before start of experimental treatment.
- Serum testosterone level < 1.7 nmol/L (50 ng/dL) at the Screening visit
Progressive disease by PSA or imaging in the setting of medical or surgical castration. Disease progression for study entry is defined as one or more of the following three criteria (according with PCWG2):
- PSA progression defined by a minimum of three rising PSA levels with an interval of ≥ 1 week between each determination. The PSA value at the Screening visit should be ≥ 2 g/L (2 ng/ml); if the third PSA value is less than second PSA, a fourth PSA must be repeated and if it the value is higher than second must be considered as disease
- Soft tissue/visceral disease progression defined by RECIST 1.1;
- Bone disease progression defined by two or more new lesions on bone scan.
Exclusion Criteria:
- Severe, concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment;
- Metastases in the brain or active epidural disease;
- History of another malignancy within the previous 5 years other than curatively treated non-melanomatous skin cancer;
- History of seizure, including any febrile seizure, loss of consciousness, or transient ischemia attack within 12 months of enrollment (Day 1 visit), or any condition that may pre-dispose to seizure (e.g., prior stroke, head trauma with loss of consciousness requiring hospitalization);
- Clinically significant cardiovascular disease including: Myocardial infarction within 6 months; Uncontrolled angina within 3 months; Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or patients with history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multi-gated acquisition scan (MUGA) performed within 3 months results in a left ventricular ejection fraction that is ≥ 45%;
- Diagnosed or suspected congenital long QT syndrome;
- History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes);
- Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer within last 3 months);
- Major surgery within 4 weeks prior to enrollment (Day 1 visit);
- Prior treatment with abiraterone acetate;
- Participation in a clinical trial about an experimental anti-androgen agent (eg. ARN-509, ODM-201, VT-464, except for placebo arm);
- Treatment (concomitant or in the previous 2 weeks) with anti-androgens (eg. Bicalutamide, nilutamide, flutamide) or 5-a reductase inhibitors (eg. finasteride, dutasteride).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Enzalutamide
All subjects will receive open label enzalutamide 160 mg (4 x 40 mg capsules), orally once daily.
|
Enzalutamide 160 mg (4 x 40 mg capsules), orally once daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Control Rate (DCR)
Time Frame: 3 months
|
To determine the clinical benefit, as measured by 3 months disease control rate (DCR) provided by enzalutamide in mCRPC patients with visceral disease.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of the treatment per NCI-CTCA v. 4.0
Time Frame: 2 years
|
To determine the safety of the treatment according to NCI-CTCA v. 4.0
|
2 years
|
Quality of life by EQ-5D-5L e FACT-P
Time Frame: 2 years
|
To evaluate quality of life as assessed by EQ-5D-5L e FACT-P questionnaire
|
2 years
|
Pain assessment
Time Frame: 2 years
|
To evaluate pain as assessed by BPI-SF questionnaire
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Elena Verzoni, MD, Fondazione IRCCS Istituto Nazionale Tumori Milano
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
- Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. No abstract available.
- Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
- Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187-97. doi: 10.1056/NEJMoa1207506. Epub 2012 Aug 15.
- Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3.
- Astellas Pharma Ltd. Xtandi (enzalutamide) 40mg soft capsules. Summary of Product Characteristics. 26 June 2013.
- Ahmed M, Li LC. Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective. Int J Urol. 2013 Apr;20(4):362-71. doi: 10.1111/iju.12005. Epub 2012 Nov 19.
- Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O; Prostate Specific Antigen Working Group. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol. 2008 Jun;179(6):2181-5; discussion 2185-6. doi: 10.1016/j.juro.2008.01.099. Epub 2008 Apr 18.
- Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Oct 30;371(18):1755-6. doi: 10.1056/NEJMc1410239. No abstract available.
- Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010 Mar;46(4):765-81. doi: 10.1016/j.ejca.2009.12.014. Epub 2010 Jan 29.
- Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol. 2014 Jun;65(6):1198-204. doi: 10.1016/j.eururo.2013.07.022. Epub 2013 Jul 25.
- Horwich A, Parker C, de Reijke T, Kataja V; ESMO Guidelines Working Group. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi106-14. doi: 10.1093/annonc/mdt208. Epub 2013 Jun 27. No abstract available.
- Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002 Feb;167(2 Pt 2):948-51; discussion 952. No abstract available.
- Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS. Drug rechallenge and treatment beyond progression--implications for drug resistance. Nat Rev Clin Oncol. 2013 Oct;10(10):571-87. doi: 10.1038/nrclinonc.2013.158. Epub 2013 Sep 3.
- Merseburger AS, Bellmunt J, Jenkins C, Parker C, Fitzpatrick JM; European Treatment Practices Group. Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist. 2013;18(5):558-67. doi: 10.1634/theoncologist.2012-0478. Epub 2013 May 13. Erratum In: Oncologist. 2013;18(6):775. Oncologist. 2013;18(8):971.
- Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10. Erratum In: N Engl J Med. 2013 Feb 7;368(6):584.
- Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol. 2011 Sep 20;29(27):3651-8. doi: 10.1200/JCO.2011.35.2005. Epub 2011 Aug 22.
- Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010 Apr 24;375(9724):1437-46. doi: 10.1016/S0140-6736(10)60172-9. Epub 2010 Apr 14.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 16, 2017
Primary Completion (Actual)
April 23, 2021
Study Completion (Actual)
April 23, 2021
Study Registration Dates
First Submitted
March 31, 2017
First Submitted That Met QC Criteria
April 5, 2017
First Posted (Actual)
April 6, 2017
Study Record Updates
Last Update Posted (Actual)
April 26, 2021
Last Update Submitted That Met QC Criteria
April 23, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INT 178-15
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma Prostate
-
University of WashingtonNational Cancer Institute (NCI)CompletedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Castration Levels of Testosterone | Stage IV Prostate AdenocarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedMetastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer | Stage IV Prostate AdenocarcinomaUnited States
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)UnknownCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the BoneUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate CarcinomaUnited States
-
University of WashingtonJanssen Research & Development, LLCTerminatedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Double-Negative Prostate CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterCompletedBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | PSA Level Greater Than FiftyUnited States
-
Emory UniversityCompletedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7United States
-
University of UtahCompletedMetastatic Prostate Carcinoma | Stage IV Prostate Cancer | Prostate Carcinoma Metastatic in the BoneUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityActive, not recruitingCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7United States
Clinical Trials on Xtandi
-
Fundación Canaria de Investigación SanitariaHospital Universitario de CanariasUnknown
-
Ricardo Pereira MestreOncology Institute of Southern Switzerland; Institute of Oncology Research; Institute...TerminatedCOVID-19 InfectionSwitzerland
-
Astellas Pharma Europe Ltd.Medivation, Inc.CompletedMetastatic Castration Resistant Prostate CancerCzechia, Netherlands, Denmark, Italy, Austria, Belgium, Bulgaria, France, Germany, Greece, Hungary, Ireland, Portugal, Slovenia, Spain, United Kingdom
-
Astellas Pharma IncPfizerCompletedCastration-resistant Prostate CancerJapan
-
Case Comprehensive Cancer CenterCompletedAdenocarcinoma of the ProstateUnited States
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedKidney Diseases | Healthy Subjects | Pharmacokinetics of MDV3100Moldova, Republic of
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedHealthy Subjects | Relative Bioavailability | Castration Resistant Prostate Cancer (CRPC) | MDV3100Germany
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedHealthy Subjects | Pharmacokinetics of MDV3100Netherlands
-
Weill Medical College of Cornell UniversitySagimet Biosciences Inc.RecruitingProstatic Neoplasms, Castration-ResistantUnited States
-
OHSU Knight Cancer InstituteAstellas Pharma US, Inc.; Oregon Health and Science UniversityActive, not recruitingCastration-Resistant Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Soft Tissues | Recurrent Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma AJCC v7 | Stage IV Prostate Adenocarcinoma AJCC v7United States